ID   CP1B1_HUMAN             Reviewed;         543 AA.
AC   Q16678; Q5TZW8; Q93089; Q9H316;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2004, sequence version 2.
DT   10-MAY-2017, entry version 197.
DE   RecName: Full=Cytochrome P450 1B1;
DE            EC=1.14.14.1 {ECO:0000269|PubMed:10426814, ECO:0000269|PubMed:22888116};
DE   AltName: Full=CYPIB1;
GN   Name=CYP1B1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=8175734;
RA   Sutter T.R., Tang Y.M., Hayes C.L., Wo Y.-Y.P., Jabs E.W., Li X.,
RA   Yin H., Cody C.W., Greenlee W.F.;
RT   "Complete cDNA sequence of a human dioxin-inducible mRNA identifies a
RT   new gene subfamily of cytochrome P450 that maps to chromosome 2.";
RL   J. Biol. Chem. 269:13092-13099(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8910454; DOI=10.1074/jbc.271.45.28324;
RA   Tang Y.M., Wo Y.-Y.P., Stewart J., Hawkins A.L., Griffin C.A.,
RA   Sutter T.R., Greenlee W.F.;
RT   "Isolation and characterization of the human cytochrome P450 CYP1B1
RT   gene.";
RL   J. Biol. Chem. 271:28324-28330(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Gorry M.C., Zhang Y., Marks J.J., Suppe B., Hart P.S., Cortelli J.R.,
RA   Pallos D., Hart T.C.;
RT   "Physical/genetic map of the 2p22-2p21 region on chromosome 2.";
RL   Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-453.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-48; SER-119;
RP   ASN-206; LEU-266; VAL-432 AND SER-453.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-112, AND VARIANT GLY-48.
RA   Guillemette C.;
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   CHARACTERIZATION OF VARIANTS SER-119 AND VAL-432.
RX   PubMed=10426814; DOI=10.1093/carcin/20.8.1607;
RA   Shimada T., Watanabe J., Kawajiri K., Sutter T.R., Guengerich F.P.,
RA   Gillam E.M.J., Inoue K.;
RT   "Catalytic properties of polymorphic human cytochrome P450 1B1
RT   variants.";
RL   Carcinogenesis 20:1607-1613(1999).
RN   [9]
RP   INVOLVEMENT IN ASGD6.
RX   PubMed=11403040; DOI=10.1136/jmg.38.5.324;
RA   Vincent A., Billingsley G., Priston M., Williams-Lyn D.,
RA   Sutherland J., Glaser T., Oliver E., Walter M.A., Heathcote G.,
RA   Levin A., Heon E.;
RT   "Phenotypic heterogeneity of CYP1B1: mutations in a patient with
RT   Peters' anomaly.";
RL   J. Med. Genet. 38:324-326(2001).
RN   [10]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15258110; DOI=10.1124/dmd.32.8.840;
RA   Choudhary D., Jansson I., Stoilov I., Sarfarazi M., Schenkman J.B.;
RT   "Metabolism of retinoids and arachidonic acid by human and mouse
RT   cytochrome P450 1b1.";
RL   Drug Metab. Dispos. 32:840-847(2004).
RN   [11]
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=22888116; DOI=10.1093/jb/mvs087;
RA   Jang H.H., Kim S.Y., Kang J.Y., Park S.H., Ryu S.H., Ahn T., Yun C.H.;
RT   "Increase of human CYP1B1 activities by acidic phospholipids and
RT   kinetic deuterium isotope effects on CYP1B1 substrate oxidation.";
RL   J. Biochem. 152:433-442(2012).
RN   [12]
RP   MUTAGENESIS OF VAL-395, AND FUNCTION IN ESTROGEN METABOLISM.
RX   PubMed=23821647; DOI=10.1124/mol.113.087700;
RA   Nishida C.R., Everett S., Ortiz de Montellano P.R.;
RT   "Specificity determinants of CYP1B1 estradiol hydroxylation.";
RL   Mol. Pharmacol. 84:451-458(2013).
RN   [13]
RP   ENZYME REGULATION.
RX   PubMed=22935222; DOI=10.1017/S0007114512003595;
RA   Poon C.H., Wong T.Y., Wang Y., Tsuchiya Y., Nakajima M., Yokoi T.,
RA   Leung L.K.;
RT   "The citrus flavanone naringenin suppresses CYP1B1 transactivation
RT   through antagonising xenobiotic-responsive element binding.";
RL   Br. J. Nutr. 109:1598-1605(2013).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 51-543 IN COMPLEX WITH HEME
RP   AND THE INHIBITOR ALPHA-NAPHTOFLAVONE, AND COFACTOR.
RX   PubMed=21147782; DOI=10.1074/jbc.M110.204420;
RA   Wang A., Savas U., Stout C.D., Johnson E.F.;
RT   "Structural characterization of the complex between alpha-
RT   naphthoflavone and human cytochrome P450 1B1.";
RL   J. Biol. Chem. 286:5736-5743(2011).
RN   [15]
RP   VARIANTS GLC3A GLU-61; ASN-374 AND TRP-469.
RX   PubMed=9463332; DOI=10.1086/301725;
RA   Bejjani B.A., Lewis R.A., Tomey K.F., Anderson K.L., Dueker D.K.,
RA   Jabak M., Astle W.F., Otterud B., Leppert M., Lupski J.R.;
RT   "Mutations in CYP1B1, the gene for cytochrome P4501B1, are the
RT   predominant cause of primary congenital glaucoma in Saudi Arabia.";
RL   Am. J. Hum. Genet. 62:325-333(1998).
RN   [16]
RP   VARIANT GLC3A TRP-365, AND VARIANTS CYS-57; GLU-61; TRP-365; LEU-379;
RP   LYS-387; HIS-390; VAL-432; LEU-437 AND TRP-469.
RX   PubMed=9497261; DOI=10.1086/301764;
RA   Stoilov I., Akarsu A.N., Alozie I., Child A., Barsoum-Homsy M.,
RA   Turacli M.E., Or M., Lewis R.A., Ozdemir N., Brice G., Aktan S.G.,
RA   Chevrette L., Coca-Prados M., Sarfarazi M.;
RT   "Sequence analysis and homology modeling suggest that primary
RT   congenital glaucoma on 2p21 results from mutations disrupting either
RT   the hinge region or the conserved core structures of cytochrome
RT   P4501B1.";
RL   Am. J. Hum. Genet. 62:573-584(1998).
RN   [17]
RP   VARIANTS VAL-432 AND SER-453.
RX   PubMed=9823305;
RA   Bailey L.R., Roodi N., Dupont W.D., Parl F.F.;
RT   "Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid
RT   receptor status in breast cancer.";
RL   Cancer Res. 58:5038-5041(1998).
RN   [18]
RP   ERRATUM.
RA   Bailey L.R., Roodi N., Dupont W.D., Parl F.F.;
RL   Cancer Res. 59:1388-1388(1999).
RN   [19]
RP   VARIANT GLC3A LYS-387.
RX   PubMed=10227395;
RA   Plasilova M., Stoilov I., Sarfarazi M., Kadasi L., Ferakova E.,
RA   Ferak V.;
RT   "Identification of a single ancestral CYP1B1 mutation in Slovak
RT   Gypsies (Roms) affected with primary congenital glaucoma.";
RL   J. Med. Genet. 36:290-294(1999).
RN   [20]
RP   VARIANTS GLC3A GLU-61; PRO-77; 269-SER--PHE-271 DEL; HIS-368; ASN-374;
RP   SER-390 AND TRP-469, AND VARIANTS GLY-48; SER-119; VAL-432 AND
RP   SER-453.
RX   PubMed=10655546; DOI=10.1093/hmg/9.3.367;
RA   Bejjani B.A., Stockton D.W., Lewis R.A., Tomey K.F., Dueker D.K.,
RA   Jabak M., Astle W.F., Lupski J.R.;
RT   "Multiple CYP1B1 mutations and incomplete penetrance in an inbred
RT   population segregating primary congenital glaucoma suggest frequent de
RT   novo events and a dominant modifier locus.";
RL   Hum. Mol. Genet. 9:367-374(2000).
RN   [21]
RP   ERRATUM.
RA   Bejjani B.A., Stockton D.W., Lewis R.A., Tomey K.F., Dueker D.K.,
RA   Jabak M., Astle W.F., Lupski J.R.;
RL   Hum. Mol. Genet. 9:1141-1141(2000).
RN   [22]
RP   VARIANT GLC3A MET-364.
RX   PubMed=11184479; DOI=10.1076/1381-6810(200009)2131-ZFT191;
RA   Ohtake Y., Kubota R., Tanino T., Miyata H., Mashima Y.;
RT   "Novel compound heterozygous mutations in the cytochrome P4501B1 gene
RT   (CYP1B1) in a Japanese patient with primary congenital glaucoma.";
RL   Ophthalmic Genet. 21:191-193(2000).
RN   [23]
RP   VARIANTS SER-119 AND VAL-432, AND ASSOCIATION WITH BREAST OR LUNG
RP   CANCER.
RX   PubMed=10739169; DOI=10.1097/00008571-200002000-00004;
RA   Watanabe J., Shimada T., Gillam E.M., Ikuta T., Suemasu K.,
RA   Higashi Y., Gotoh O., Kawajiri K.;
RT   "Association of CYP1B1 genetic polymorphism with incidence to breast
RT   and lung cancer.";
RL   Pharmacogenetics 10:25-33(2000).
RN   [24]
RP   VARIANTS GLC3A VAL-192; ILE-198; LEU-320; PHE-330; MET-364; GLN-444
RP   AND GLY-499, AND VARIANTS GLY-48; SER-119 AND VAL-432.
RX   PubMed=11527932;
RA   Mashima Y., Suzuki Y., Sergeev Y., Ohtake Y., Tanino T., Kimura I.,
RA   Miyata H., Aihara M., Tanihara H., Inatani M., Azuma N., Iwata T.,
RA   Araie M.;
RT   "Novel cytochrome P4501B1 (CYP1B1) gene mutations in Japanese patients
RT   with primary congenital glaucoma.";
RL   Invest. Ophthalmol. Vis. Sci. 42:2211-2216(2001).
RN   [25]
RP   ERRATUM.
RA   Mashima Y., Suzuki Y., Sergeev Y., Ohtake Y., Tanino T., Kimura I.,
RA   Miyata H., Aihara M., Tanihara H., Inatani M., Azuma N., Iwata T.,
RA   Araie M.;
RL   Invest. Ophthalmol. Vis. Sci. 42:2775-2775(2001).
RN   [26]
RP   VARIANT POAG PHE-345, VARIANT GLC1A HIS-368, AND VARIANT VAL-432.
RX   PubMed=11774072; DOI=10.1086/338709;
RA   Vincent A.L., Billingsley G., Buys Y., Levin A.V., Priston M.,
RA   Trope G., Williams-Lyn D., Heon E.;
RT   "Digenic inheritance of early-onset glaucoma: CYP1B1, a potential
RT   modifier gene.";
RL   Am. J. Hum. Genet. 70:448-460(2002).
RN   [27]
RP   VARIANTS GLC3A GLU-61; LEU-193; LYS-229 AND HIS-368, AND VARIANTS
RP   GLY-48; SER-184 AND VAL-432.
RX   PubMed=11980847;
RA   Panicker S.G., Reddy A.B.M., Mandal A.K., Ahmed N., Nagarajaram H.A.,
RA   Hasnain S.E., Balasubramanian D.;
RT   "Identification of novel mutations causing familial primary congenital
RT   glaucoma in Indian pedigrees.";
RL   Invest. Ophthalmol. Vis. Sci. 43:1358-1366(2002).
RN   [28]
RP   VARIANTS GLC3A HIS-368; LYS-387; LEU-437 AND GLY-443, AND VARIANTS
RP   GLY-48; SER-119; VAL-432 AND SER-453.
RX   PubMed=12036985;
RA   Stoilov I.R., Costa V.P., Vasconcellos J.P.C., Melo M.B.,
RA   Betinjane A.J., Carani J.C.E., Oltrogge E.V., Sarfarazi M.;
RT   "Molecular genetics of primary congenital glaucoma in Brazil.";
RL   Invest. Ophthalmol. Vis. Sci. 43:1820-1827(2002).
RN   [29]
RP   VARIANTS GLY-48; SER-119; VAL-432; GLY-443 AND SER-453.
RX   PubMed=11854439; DOI=10.1124/mol.61.3.586;
RA   Aklillu E., Oscarson M., Hidestrand M., Leidvik B., Otter C.,
RA   Ingelman-Sundberg M.;
RT   "Functional analysis of six different polymorphic CYP1B1 enzyme
RT   variants found in an Ethiopian population.";
RL   Mol. Pharmacol. 61:586-594(2002).
RN   [30]
RP   VARIANTS GLC3A ARG-144 AND CYS-445.
RX   PubMed=14640114; DOI=10.1007/s00439-003-1035-0;
RA   Chakrabarti S., Komatireddy S., Mandal A.K., Balasubramanian D.;
RT   "Gene symbol: CYP1B1. Disease: glaucoma, primary congenital.";
RL   Hum. Genet. 113:556-558(2003).
RN   [31]
RP   VARIANTS GLC3A LYS-229; ARG-232; LYS-387; SER-390; SER-399 AND
RP   TYR-423, AND VARIANTS GLY-48; SER-119; VAL-432 AND SER-453.
RX   PubMed=14635112; DOI=10.1002/humu.9197;
RA   Colomb E., Kaplan J., Garchon H.-J.;
RT   "Novel cytochrome P450 1B1 (CYP1B1) mutations in patients with primary
RT   congenital glaucoma in France.";
RL   Hum. Mutat. 22:496-496(2003).
RN   [32]
RP   VARIANTS GLC3A ILE-215; 355-ARG--ALA-358 DEL AND MET-364, AND VARIANTS
RP   GLY-48; SER-119; VAL-432 AND SER-453.
RX   PubMed=12525557; DOI=10.1136/jmg.40.1.e9;
RA   Sitorus R., Ardjo S.M., Lorenz B., Preising M.;
RT   "CYP1B1 gene analysis in primary congenital glaucoma in Indonesian and
RT   European patients.";
RL   J. Med. Genet. 40:E9-E9(2003).
RN   [33]
RP   VARIANTS POAG ASN-81; LYS-229; ARG-232; SER-269--PHE-271 DEL; LYS-387;
RP   HIS-390; TYR-423 AND GLY-443, VARIANTS GLC3A ARG-232; LYS-387 AND
RP   TYR-423, AND VARIANTS GLY-48; SER119; VAL-432 AND SER-453.
RX   PubMed=15342693; DOI=10.1136/jmg.2004.020024;
RA   Melki R., Colomb E., Lefort N., Brezin A.P., Garchon H.-J.;
RT   "CYP1B1 mutations in French patients with early-onset primary open-
RT   angle glaucoma.";
RL   J. Med. Genet. 41:647-651(2004).
RN   [34]
RP   VARIANTS GLC3A PRO-77; PRO-115; ARG-132; PRO-144; LEU-193; LYS-229;
RP   ARG-239; HIS-368; HIS-390; CYS-390; LEU-437 AND ASP-466, AND VARIANTS
RP   GLY-48; SER-119; VAL-432 AND SER-453.
RX   PubMed=15475877;
RA   Reddy A.B.M., Kaur K., Mandal A.K., Panicker S.G., Thomas R.,
RA   Hasnain S.E., Balasubramanian D., Chakrabarti S.;
RT   "Mutation spectrum of the CYP1B1 gene in Indian primary congenital
RT   glaucoma patients.";
RL   Mol. Vis. 10:696-702(2004).
RN   [35]
RP   VARIANT GLC3A CYS-390.
RX   PubMed=15255109; DOI=10.1076/opge.25.1.3.28999;
RA   Curry S.M., Daou A.G., Hermanns P., Molinari A., Lewis R.A.,
RA   Bejjani B.A.;
RT   "Cytochrome P4501B1 mutations cause only part of primary congenital
RT   glaucoma in Ecuador.";
RL   Ophthalmic Genet. 25:3-9(2004).
RN   [36]
RP   VARIANTS GLC3A GLU-61; HIS-368 AND THR-388, AND VARIANT GLY-422.
RX   PubMed=16490498; DOI=10.1016/j.ajo.2005.11.001;
RA   Alfadhli S., Behbehani A., Elshafey A., Abdelmoaty S., Al-Awadi S.;
RT   "Molecular and clinical evaluation of primary congenital glaucoma in
RT   Kuwait.";
RL   Am. J. Ophthalmol. 141:512-516(2006).
RN   [37]
RP   VARIANTS POAG CYS-57; LYS-229; HIS-368; LEU-515; THR-523 AND GLY-530,
RP   AND VARIANTS GLY-48; SER-119; VAL-432; SER-453 AND ALA-518.
RX   PubMed=16688110;
RA   Acharya M., Mookherjee S., Bhattacharjee A., Bandyopadhyay A.K.,
RA   Daulat Thakur S.K., Bhaduri G., Sen A., Ray K.;
RT   "Primary role of CYP1B1 in Indian juvenile-onset POAG patients.";
RL   Mol. Vis. 12:399-404(2006).
RN   [38]
RP   VARIANTS GLC3A GLU-61; ASN-81; LYS-229; LEU-343 DEL; HIS-368; LYS-387
RP   AND TRP-469.
RX   PubMed=16735994;
RA   Chavarria-Soley G., Michels-Rautenstrauss K., Pasutto F., Flikier D.,
RA   Flikier P., Cirak S., Bejjani B., Winters D.L., Lewis R.A., Mardin C.,
RA   Reis A., Rautenstrauss B.;
RT   "Primary congenital glaucoma and Rieger's anomaly: extended haplotypes
RT   reveal founder effects for eight distinct CYP1B1 mutations.";
RL   Mol. Vis. 12:523-531(2006).
RN   [39]
RP   VARIANTS POAG TRP-28; GLU-61; ASN-81; TRP-145; LYS-229; PHE-409 AND
RP   GLY-443, AND VARIANTS LEU-52; HIS-144; PRO-189 AND SER-330.
RX   PubMed=16862072;
RA   Lopez-Garrido M.-P., Sanchez-Sanchez F., Lopez-Martinez F.,
RA   Aroca-Aguilar J.-D., Blanco-Marchite C., Coca-Prados M., Escribano J.;
RT   "Heterozygous CYP1B1 gene mutations in Spanish patients with primary
RT   open-angle glaucoma.";
RL   Mol. Vis. 12:748-755(2006).
RN   [40]
RP   CHARACTERIZATION OF VARIANTS GLC3A GLU-61; SER-203; LYS-229 AND
RP   LEU-343 DEL, AND CHARACTERIZATION OF VARIANT POAG ASN-81.
RX   PubMed=18470941; DOI=10.1002/humu.20786;
RA   Chavarria-Soley G., Sticht H., Aklillu E., Ingelman-Sundberg M.,
RA   Pasutto F., Reis A., Rautenstrauss B.;
RT   "Mutations in CYP1B1 cause primary congenital glaucoma by reduction of
RT   either activity or abundance of the enzyme.";
RL   Hum. Mutat. 29:1147-1153(2008).
CC   -!- FUNCTION: Cytochromes P450 are a group of heme-thiolate
CC       monooxygenases. In liver microsomes, this enzyme is involved in an
CC       NADPH-dependent electron transport pathway. It oxidizes a variety
CC       of structurally unrelated compounds, including steroids, fatty
CC       acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-
CC       estradiol to the carcinogenic 4-hydroxy derivative, and a variety
CC       of procarcinogenic compounds to their activated forms, including
CC       polycyclic aromatic hydrocarbons. Promotes angiogenesis by
CC       removing cellular oxygenation products, thereby decreasing
CC       oxidative stress, release of antiangiogenic factor THBS2, then
CC       allowing endothelial cells migration, cell adhesion and capillary
CC       morphogenesis. These changes are concommitant with the endothelial
CC       nitric oxide synthase activity and nitric oxide synthesis. Plays
CC       an important role in the regulation of perivascular cell
CC       proliferation, migration, and survival through modulation of the
CC       intracellular oxidative state and NF-kappa-B expression and/or
CC       activity, during angiogenesis. Contributes to oxidative
CC       homeostasis and ultrastructural organization and function of
CC       trabecular meshwork tissue through modulation of POSTN expression.
CC       {ECO:0000269|PubMed:10426814, ECO:0000269|PubMed:15258110,
CC       ECO:0000269|PubMed:22888116, ECO:0000269|PubMed:23821647}.
CC   -!- CATALYTIC ACTIVITY: RH + [reduced NADPH--hemoprotein reductase] +
CC       O(2) = ROH + [oxidized NADPH--hemoprotein reductase] + H(2)O.
CC       {ECO:0000269|PubMed:10426814, ECO:0000269|PubMed:22888116}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000269|PubMed:21147782};
CC   -!- ENZYME REGULATION: Enzyme activity is increased by liposomes
CC       containing anionic phospholipids, phosphatidic acid and
CC       cardiolipin. Inhibited by naringenin with an IC(50) of 5 uM.
CC       {ECO:0000269|PubMed:22888116, ECO:0000269|PubMed:22935222}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.0 uM for 17-beta-estradiol {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         KM=17.0 uM for testosterone {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         KM=24.0 uM for progesterone {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         KM=18.5 uM for retinol {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         KM=8.5 uM for retinal {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         KM=29.8 uM for arachidonic acid {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         KM=212.8 uM for 7,12-dimethyltetraphene
CC         {ECO:0000269|PubMed:10426814, ECO:0000269|PubMed:15258110};
CC         Vmax=14.95 nmol/min/mg enzyme for 17-beta-estradiol 4-
CC         hydroxylation {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         Vmax=6.9 nmol/min/mg enzyme for 17-beta-estradiol 2-
CC         hydroxylation {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         Vmax=36.16 nmol/min/mg enzyme for testosterone 6-beta-
CC         hydroxylation {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         Vmax=9.86 nmol/min/mg enzyme for progesterone 6-beta-
CC         hydroxylation {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         Vmax=37.80 nmol/min/mg enzyme for progesterone 16-alpha-
CC         hydroxylation {ECO:0000269|PubMed:10426814,
CC         ECO:0000269|PubMed:15258110};
CC         Note=kcat is 0.15 min(-1) for retinol, 0.77 min(-1) for retinal,
CC         2.86 min(-1) for 7,12-dimethyltetraphene, 0.48 min(-1) for
CC         arachidonic acid.;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein. Microsome membrane; Peripheral membrane protein.
CC       Mitochondrion {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in many tissues.
CC       {ECO:0000269|PubMed:8175734}.
CC   -!- INDUCTION: By polycyclic aromatic hydrocarbons (PAH) and 2,3,7,8-
CC       tetrachlorodibenzo-p-dioxin (TCDD). {ECO:0000269|PubMed:8175734}.
CC   -!- POLYMORPHISM: Various CYP1B1 alleles are known. The sequence shown
CC       is that of allele CYP1B1*1.
CC   -!- DISEASE: Anterior segment dysgenesis 6 (ASGD6) [MIM:617315]: A
CC       form of anterior segment dysgenesis, a group of defects affecting
CC       anterior structures of the eye including cornea, iris, lens,
CC       trabecular meshwork, and Schlemm canal. Anterior segment
CC       dysgeneses result from abnormal migration or differentiation of
CC       the neural crest derived mesenchymal cells that give rise to
CC       components of the anterior chamber during eye development.
CC       Different anterior segment anomalies may exist alone or in
CC       combination, including iris hypoplasia, enlarged or reduced
CC       corneal diameter, corneal vascularization and opacity, posterior
CC       embryotoxon, corectopia, polycoria, abnormal iridocorneal angle,
CC       ectopia lentis, and anterior synechiae between the iris and
CC       posterior corneal surface. Clinical conditions falling within the
CC       phenotypic spectrum of anterior segment dysgeneses include
CC       aniridia, Axenfeld anomaly, Reiger anomaly/syndrome, Peters
CC       anomaly, and iridogoniodysgenesis. ASGD6 patients predominantly
CC       manifest Peters anomaly. Peters anomaly consists of corneal
CC       leukoma, defects in the posterior structures of the cornea such as
CC       absence of the posterior corneal stroma and Descemet membrane, and
CC       a variable degree of iridocorneal and/or keratolenticular
CC       adhesions. Over 50% of patients develop glaucoma in childhood.
CC       {ECO:0000269|PubMed:11403040}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Glaucoma 3, primary congenital, A (GLC3A) [MIM:231300]:
CC       An autosomal recessive form of primary congenital glaucoma (PCG).
CC       PCG is characterized by marked increase of intraocular pressure at
CC       birth or early childhood, large ocular globes (buphthalmos) and
CC       corneal edema. It results from developmental defects of the
CC       trabecular meshwork and anterior chamber angle of the eye that
CC       prevent adequate drainage of aqueous humor.
CC       {ECO:0000269|PubMed:10227395, ECO:0000269|PubMed:10655546,
CC       ECO:0000269|PubMed:11184479, ECO:0000269|PubMed:11527932,
CC       ECO:0000269|PubMed:11980847, ECO:0000269|PubMed:12036985,
CC       ECO:0000269|PubMed:12525557, ECO:0000269|PubMed:14635112,
CC       ECO:0000269|PubMed:14640114, ECO:0000269|PubMed:15255109,
CC       ECO:0000269|PubMed:15342693, ECO:0000269|PubMed:15475877,
CC       ECO:0000269|PubMed:16490498, ECO:0000269|PubMed:16735994,
CC       ECO:0000269|PubMed:18470941, ECO:0000269|PubMed:9463332,
CC       ECO:0000269|PubMed:9497261}. Note=The disease is caused by
CC       mutations affecting distinct genetic loci, including the gene
CC       represented in this entry.
CC   -!- DISEASE: Glaucoma, primary open angle (POAG) [MIM:137760]: A
CC       complex and genetically heterogeneous ocular disorder
CC       characterized by a specific pattern of optic nerve and visual
CC       field defects. The angle of the anterior chamber of the eye is
CC       open, and usually the intraocular pressure is increased. However,
CC       glaucoma can occur at any intraocular pressure. The disease is
CC       generally asymptomatic until the late stages, by which time
CC       significant and irreversible optic nerve damage has already taken
CC       place. In some cases, POAG shows digenic inheritance involving
CC       mutations in CYP1B1 and MYOC genes. {ECO:0000269|PubMed:11774072,
CC       ECO:0000269|PubMed:15342693, ECO:0000269|PubMed:16688110,
CC       ECO:0000269|PubMed:16862072, ECO:0000269|PubMed:18470941}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry. CYP1B1 mutations
CC       have been reported to pose a significant risk for early-onset POAG
CC       and also modify glaucoma phenotype in patients who do not carry a
CC       MYOC mutation (PubMed:15342693). {ECO:0000269|PubMed:15342693}.
CC   -!- DISEASE: Glaucoma 1, open angle, A (GLC1A) [MIM:137750]: A form of
CC       primary open angle glaucoma (POAG). POAG is characterized by a
CC       specific pattern of optic nerve and visual field defects. The
CC       angle of the anterior chamber of the eye is open, and usually the
CC       intraocular pressure is increased. However, glaucoma can occur at
CC       any intraocular pressure. The disease is generally asymptomatic
CC       until the late stages, by which time significant and irreversible
CC       optic nerve damage has already taken place.
CC       {ECO:0000269|PubMed:11774072}. Note=The gene represented in this
CC       entry acts as a disease modifier. Digenic mutations in CYP1B1 and
CC       MYOC have been found in a family segregating both primary adult-
CC       onset and juvenile forms of open angle glaucoma (PubMed:11774072).
CC       All affected family members with mutations in both MYOC and CYP1B1
CC       had juvenile glaucoma, whereas those with only the MYOC mutation
CC       had the adult-onset form (PubMed:11774072).
CC       {ECO:0000269|PubMed:11774072}.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Cytochrome P450 Allele Nomenclature Committee;
CC       Note=CYP1B1 alleles;
CC       URL="http://www.cypalleles.ki.se/cyp1b1.htm";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cyp1b1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U03688; AAA19567.1; -; mRNA.
DR   EMBL; U56438; AAC50809.1; -; Genomic_DNA.
DR   EMBL; AF450132; AAM50512.1; -; Genomic_DNA.
DR   EMBL; AF450131; AAM50512.1; JOINED; Genomic_DNA.
DR   EMBL; BT019979; AAV38782.1; -; mRNA.
DR   EMBL; AY393998; AAQ87875.1; -; Genomic_DNA.
DR   EMBL; BC012049; AAH12049.1; -; mRNA.
DR   EMBL; AF171066; AAG43404.1; -; Genomic_DNA.
DR   CCDS; CCDS1793.1; -.
DR   PIR; A54116; A54116.
DR   RefSeq; NP_000095.2; NM_000104.3.
DR   UniGene; Hs.154654; -.
DR   PDB; 3PM0; X-ray; 2.70 A; A=51-543.
DR   PDBsum; 3PM0; -.
DR   ProteinModelPortal; Q16678; -.
DR   SMR; Q16678; -.
DR   BioGrid; 107925; 2.
DR   IntAct; Q16678; 1.
DR   STRING; 9606.ENSP00000260630; -.
DR   BindingDB; Q16678; -.
DR   ChEMBL; CHEMBL4878; -.
DR   DrugBank; DB02342; 2-Methoxyestradiol.
DR   DrugBank; DB00613; Amodiaquine.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   DrugBank; DB00121; Biotin.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00694; Daunorubicin.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB01248; Docetaxel.
DR   DrugBank; DB00997; Doxorubicin.
DR   DrugBank; DB00530; Erlotinib.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB00655; Estrone.
DR   DrugBank; DB00499; Flutamide.
DR   DrugBank; DB01026; Ketoconazole.
DR   DrugBank; DB00448; Lansoprazole.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB01204; Mitoxantrone.
DR   DrugBank; DB00338; Omeprazole.
DR   DrugBank; DB00526; Oxaliplatin.
DR   DrugBank; DB01229; Paclitaxel.
DR   DrugBank; DB01174; Phenobarbital.
DR   DrugBank; DB01087; Primaquine.
DR   DrugBank; DB01168; Procarbazine.
DR   DrugBank; DB00396; Progesterone.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB02709; Resveratrol.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB00624; Testosterone.
DR   DrugBank; DB00277; Theophylline.
DR   GuidetoPHARMACOLOGY; 1320; -.
DR   SwissLipids; SLP:000001331; -.
DR   iPTMnet; Q16678; -.
DR   PhosphoSitePlus; Q16678; -.
DR   BioMuta; CYP1B1; -.
DR   DMDM; 48429256; -.
DR   EPD; Q16678; -.
DR   MaxQB; Q16678; -.
DR   PaxDb; Q16678; -.
DR   PeptideAtlas; Q16678; -.
DR   PRIDE; Q16678; -.
DR   DNASU; 1545; -.
DR   Ensembl; ENST00000610745; ENSP00000478561; ENSG00000138061.
DR   Ensembl; ENST00000614273; ENSP00000483678; ENSG00000138061.
DR   GeneID; 1545; -.
DR   KEGG; hsa:1545; -.
DR   UCSC; uc032njx.2; human.
DR   CTD; 1545; -.
DR   DisGeNET; 1545; -.
DR   GeneCards; CYP1B1; -.
DR   GeneReviews; CYP1B1; -.
DR   H-InvDB; HIX0001979; -.
DR   HGNC; HGNC:2597; CYP1B1.
DR   HPA; CAB011705; -.
DR   HPA; HPA026863; -.
DR   MalaCards; CYP1B1; -.
DR   MIM; 137750; phenotype.
DR   MIM; 137760; phenotype.
DR   MIM; 231300; phenotype.
DR   MIM; 601771; gene.
DR   MIM; 617315; phenotype.
DR   neXtProt; NX_Q16678; -.
DR   OpenTargets; ENSG00000138061; -.
DR   Orphanet; 98976; Congenital glaucoma.
DR   Orphanet; 98977; Juvenile glaucoma.
DR   Orphanet; 708; Peters anomaly.
DR   Orphanet; 353225; Primary adult open-angle glaucoma.
DR   PharmGKB; PA27094; -.
DR   eggNOG; KOG0156; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00760000118992; -.
DR   HOGENOM; HOG000036991; -.
DR   HOVERGEN; HBG106944; -.
DR   InParanoid; Q16678; -.
DR   KO; K07410; -.
DR   OMA; MAFGHYS; -.
DR   OrthoDB; EOG091G0BT8; -.
DR   PhylomeDB; Q16678; -.
DR   TreeFam; TF105095; -.
DR   BioCyc; MetaCyc:HS06443-MONOMER; -.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   Reactome; R-HSA-2142670; Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET).
DR   Reactome; R-HSA-2142816; Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE).
DR   SABIO-RK; Q16678; -.
DR   ChiTaRS; CYP1B1; human.
DR   EvolutionaryTrace; Q16678; -.
DR   GeneWiki; CYP1B1; -.
DR   GenomeRNAi; 1545; -.
DR   PRO; PR:Q16678; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000138061; -.
DR   CleanEx; HS_CYP1B1; -.
DR   ExpressionAtlas; Q16678; baseline and differential.
DR   Genevisible; Q16678; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070330; F:aromatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004497; F:monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0016712; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; IDA:MGI.
DR   GO; GO:0019825; F:oxygen binding; TAS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; ISS:UniProtKB.
DR   GO; GO:0006725; P:cellular aromatic compound metabolic process; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; ISS:UniProtKB.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:MGI.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:UniProtKB.
DR   GO; GO:0043542; P:endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0071603; P:endothelial cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0019373; P:epoxygenase P450 pathway; TAS:Reactome.
DR   GO; GO:0008210; P:estrogen metabolic process; IDA:UniProtKB.
DR   GO; GO:0008631; P:intrinsic apoptotic signaling pathway in response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0046466; P:membrane lipid catabolic process; ISS:UniProtKB.
DR   GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; ISS:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0097267; P:omega-hydroxylase P450 pathway; TAS:Reactome.
DR   GO; GO:0055114; P:oxidation-reduction process; TAS:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; ISS:UniProtKB.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; ISS:UniProtKB.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; ISS:UniProtKB.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0061304; P:retinal blood vessel morphogenesis; ISS:UniProtKB.
DR   GO; GO:0042574; P:retinal metabolic process; IDA:UniProtKB.
DR   GO; GO:0042572; P:retinol metabolic process; IDA:UniProtKB.
DR   GO; GO:0008202; P:steroid metabolic process; IDA:UniProtKB.
DR   GO; GO:0016125; P:sterol metabolic process; TAS:Reactome.
DR   GO; GO:0009404; P:toxin metabolic process; IEA:Ensembl.
DR   GO; GO:0002930; P:trabecular meshwork development; ISS:UniProtKB.
DR   GO; GO:0007601; P:visual perception; TAS:UniProtKB.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IDA:UniProtKB.
DR   InterPro; IPR032971; CYP1B1.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   PANTHER; PTHR24299:SF16; PTHR24299:SF16; 1.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disease mutation;
KW   Endoplasmic reticulum; Glaucoma; Heme; Iron; Membrane; Metal-binding;
KW   Microsome; Mitochondrion; Monooxygenase; Oxidoreductase;
KW   Peters anomaly; Polymorphism; Reference proteome.
FT   CHAIN         1    543       Cytochrome P450 1B1.
FT                                /FTId=PRO_0000051660.
FT   METAL       470    470       Iron (heme axial ligand).
FT                                {ECO:0000244|PDB:3PM0,
FT                                ECO:0000269|PubMed:21147782}.
FT   SITE        395    395       Major determinant of CYP1B1 17beta-
FT                                estradiol hydroxylation regiospecificity.
FT   VARIANT      28     28       S -> W (in POAG; dbSNP:rs780002791).
FT                                {ECO:0000269|PubMed:16862072}.
FT                                /FTId=VAR_054227.
FT   VARIANT      48     48       R -> G (in allele CYP1B1*2, allele
FT                                CYP1B1*5, allele CYP1B1*6 and allele
FT                                CYP1B1*7; dbSNP:rs10012).
FT                                {ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:11527932,
FT                                ECO:0000269|PubMed:11854439,
FT                                ECO:0000269|PubMed:11980847,
FT                                ECO:0000269|PubMed:12036985,
FT                                ECO:0000269|PubMed:12525557,
FT                                ECO:0000269|PubMed:14635112,
FT                                ECO:0000269|PubMed:15342693,
FT                                ECO:0000269|PubMed:15475877,
FT                                ECO:0000269|PubMed:16688110,
FT                                ECO:0000269|Ref.5, ECO:0000269|Ref.7}.
FT                                /FTId=VAR_011752.
FT   VARIANT      52     52       P -> L (in dbSNP:rs201824781).
FT                                {ECO:0000269|PubMed:16862072}.
FT                                /FTId=VAR_054228.
FT   VARIANT      57     57       W -> C (in POAG; juvenile onset; allele
FT                                CYP1B1*11; dbSNP:rs72549387).
FT                                {ECO:0000269|PubMed:16688110,
FT                                ECO:0000269|PubMed:9497261}.
FT                                /FTId=VAR_008350.
FT   VARIANT      61     61       G -> E (in GLC3A and POAG; allele
FT                                CYP1B1*12; reduces enzymatic activity;
FT                                dbSNP:rs28936700).
FT                                {ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:11980847,
FT                                ECO:0000269|PubMed:16490498,
FT                                ECO:0000269|PubMed:16735994,
FT                                ECO:0000269|PubMed:16862072,
FT                                ECO:0000269|PubMed:18470941,
FT                                ECO:0000269|PubMed:9463332,
FT                                ECO:0000269|PubMed:9497261}.
FT                                /FTId=VAR_001244.
FT   VARIANT      68     68       Q -> R (in dbSNP:rs9282670).
FT                                /FTId=VAR_028735.
FT   VARIANT      77     77       L -> P (in GLC3A).
FT                                {ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:15475877}.
FT                                /FTId=VAR_054229.
FT   VARIANT      81     81       Y -> N (in POAG; adult-onset; hypomorphic
FT                                allele; reduces the abundance of the
FT                                enzyme; dbSNP:rs9282671).
FT                                {ECO:0000269|PubMed:15342693,
FT                                ECO:0000269|PubMed:16735994,
FT                                ECO:0000269|PubMed:16862072,
FT                                ECO:0000269|PubMed:18470941}.
FT                                /FTId=VAR_028736.
FT   VARIANT     115    115       A -> P (in GLC3A; dbSNP:rs764338357).
FT                                {ECO:0000269|PubMed:15475877}.
FT                                /FTId=VAR_054230.
FT   VARIANT     119    119       A -> S (in allele CYP1B1*2, allele
FT                                CYP1B1*6 and allele CYP1B1*7;
FT                                significantly associated with breast or
FT                                lung cancer; no significant change in
FT                                17beta-estradiol 2- and 4-hydroxylation
FT                                activities and 17beta-estradiol affinity;
FT                                1.5-fold reduction in testosterone
FT                                affinity but nearly no change in
FT                                testosterone 6beta-hydroxylation
FT                                activity; 2-fold increase in progesterone
FT                                6beta- and 16alpha-hydroxylation
FT                                activities and 5-fold reduction in
FT                                progesterone affinity; dbSNP:rs1056827).
FT                                {ECO:0000269|PubMed:10426814,
FT                                ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:10739169,
FT                                ECO:0000269|PubMed:11527932,
FT                                ECO:0000269|PubMed:11854439,
FT                                ECO:0000269|PubMed:12036985,
FT                                ECO:0000269|PubMed:12525557,
FT                                ECO:0000269|PubMed:14635112,
FT                                ECO:0000269|PubMed:15475877,
FT                                ECO:0000269|PubMed:16688110,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011753.
FT   VARIANT     132    132       M -> R (in GLC3A).
FT                                {ECO:0000269|PubMed:15475877}.
FT                                /FTId=VAR_054231.
FT   VARIANT     144    144       Q -> H. {ECO:0000269|PubMed:16862072}.
FT                                /FTId=VAR_054232.
FT   VARIANT     144    144       Q -> P (in GLC3A).
FT                                {ECO:0000269|PubMed:15475877}.
FT                                /FTId=VAR_054233.
FT   VARIANT     144    144       Q -> R (in GLC3A; dbSNP:rs753847648).
FT                                {ECO:0000269|PubMed:14640114}.
FT                                /FTId=VAR_054234.
FT   VARIANT     145    145       R -> W (in POAG).
FT                                {ECO:0000269|PubMed:16862072}.
FT                                /FTId=VAR_054235.
FT   VARIANT     184    184       G -> S. {ECO:0000269|PubMed:11980847}.
FT                                /FTId=VAR_054236.
FT   VARIANT     189    189       A -> P (associated with ocular
FT                                hypertension susceptibility).
FT                                {ECO:0000269|PubMed:16862072}.
FT                                /FTId=VAR_054237.
FT   VARIANT     192    192       D -> V (in GLC3A).
FT                                {ECO:0000269|PubMed:11527932}.
FT                                /FTId=VAR_054238.
FT   VARIANT     193    193       P -> L (in GLC3A; dbSNP:rs529769268).
FT                                {ECO:0000269|PubMed:11980847,
FT                                ECO:0000269|PubMed:15475877}.
FT                                /FTId=VAR_054239.
FT   VARIANT     198    198       V -> I (in GLC3A; dbSNP:rs59472972).
FT                                {ECO:0000269|PubMed:11527932}.
FT                                /FTId=VAR_054240.
FT   VARIANT     203    203       N -> S (in GLC3A; reduces enzymatic
FT                                activity). {ECO:0000269|PubMed:18470941}.
FT                                /FTId=VAR_054241.
FT   VARIANT     206    206       S -> N (in dbSNP:rs9341248).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_018869.
FT   VARIANT     215    215       S -> I (in GLC3A; dbSNP:rs72549384).
FT                                {ECO:0000269|PubMed:12525557}.
FT                                /FTId=VAR_054242.
FT   VARIANT     229    229       E -> K (in GLC3A and POAG; juvenile-
FT                                onset; hypomorphic allele; reduces the
FT                                abundance of the enzyme;
FT                                dbSNP:rs57865060).
FT                                {ECO:0000269|PubMed:11980847,
FT                                ECO:0000269|PubMed:14635112,
FT                                ECO:0000269|PubMed:15342693,
FT                                ECO:0000269|PubMed:15475877,
FT                                ECO:0000269|PubMed:16688110,
FT                                ECO:0000269|PubMed:16735994,
FT                                ECO:0000269|PubMed:16862072,
FT                                ECO:0000269|PubMed:18470941}.
FT                                /FTId=VAR_054243.
FT   VARIANT     232    232       G -> R (in GLC3A and POAG; adult-onset;
FT                                dbSNP:rs104893628).
FT                                {ECO:0000269|PubMed:14635112,
FT                                ECO:0000269|PubMed:15342693}.
FT                                /FTId=VAR_054244.
FT   VARIANT     239    239       S -> R (in GLC3A).
FT                                {ECO:0000269|PubMed:15475877}.
FT                                /FTId=VAR_054245.
FT   VARIANT     266    266       R -> L (in dbSNP:rs9341250).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_018870.
FT   VARIANT     269    271       Missing (in GLC3A and POAG).
FT                                {ECO:0000269|PubMed:10655546}.
FT                                /FTId=VAR_054246.
FT   VARIANT     320    320       V -> L (in GLC3A; dbSNP:rs72549382).
FT                                {ECO:0000269|PubMed:11527932}.
FT                                /FTId=VAR_054247.
FT   VARIANT     330    330       A -> F (in GLC3A; requires 2 nucleotide
FT                                substitutions; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11527932}.
FT                                /FTId=VAR_054248.
FT   VARIANT     330    330       A -> S (associated with ocular
FT                                hypertension susceptibility).
FT                                {ECO:0000269|PubMed:16862072}.
FT                                /FTId=VAR_054249.
FT   VARIANT     343    343       Missing (in GLC3A; reduces enzymatic
FT                                activity and also the abundance of the
FT                                enzyme). {ECO:0000269|PubMed:16735994,
FT                                ECO:0000269|PubMed:18470941}.
FT                                /FTId=VAR_054250.
FT   VARIANT     345    345       L -> F (in POAG; dbSNP:rs66583685).
FT                                {ECO:0000269|PubMed:11774072}.
FT                                /FTId=VAR_054251.
FT   VARIANT     355    358       Missing (in GLC3A).
FT                                {ECO:0000269|PubMed:12525557}.
FT                                /FTId=VAR_054252.
FT   VARIANT     364    364       V -> M (in GLC3A; dbSNP:rs72549379).
FT                                {ECO:0000269|PubMed:11184479,
FT                                ECO:0000269|PubMed:11527932,
FT                                ECO:0000269|PubMed:12525557}.
FT                                /FTId=VAR_054253.
FT   VARIANT     365    365       G -> W (in GLC3A; allele CYP1B1*18;
FT                                dbSNP:rs55771538).
FT                                {ECO:0000269|PubMed:9497261}.
FT                                /FTId=VAR_001245.
FT   VARIANT     368    368       R -> H (in GLC3A and GLC1A; acts as GLC1A
FT                                disease modifier in patients also
FT                                carrying Val-399 mutation in MYOC;
FT                                dbSNP:rs79204362).
FT                                {ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:11774072,
FT                                ECO:0000269|PubMed:11980847,
FT                                ECO:0000269|PubMed:12036985,
FT                                ECO:0000269|PubMed:15475877,
FT                                ECO:0000269|PubMed:16490498,
FT                                ECO:0000269|PubMed:16688110,
FT                                ECO:0000269|PubMed:16735994}.
FT                                /FTId=VAR_016034.
FT   VARIANT     374    374       D -> N (in GLC3A; dbSNP:rs28936413).
FT                                {ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:9463332}.
FT                                /FTId=VAR_001246.
FT   VARIANT     379    379       P -> L (in allele CYP1B1*19;
FT                                dbSNP:rs56305281).
FT                                {ECO:0000269|PubMed:9497261}.
FT                                /FTId=VAR_008351.
FT   VARIANT     387    387       E -> K (in GLC3A and POAG; allele
FT                                CYP1B1*20; dbSNP:rs55989760).
FT                                {ECO:0000269|PubMed:10227395,
FT                                ECO:0000269|PubMed:12036985,
FT                                ECO:0000269|PubMed:14635112,
FT                                ECO:0000269|PubMed:15342693,
FT                                ECO:0000269|PubMed:16735994,
FT                                ECO:0000269|PubMed:9497261}.
FT                                /FTId=VAR_008352.
FT   VARIANT     388    388       A -> T (in GLC3A).
FT                                {ECO:0000269|PubMed:16490498}.
FT                                /FTId=VAR_054254.
FT   VARIANT     390    390       R -> C (in GLC3A; dbSNP:rs148542782).
FT                                {ECO:0000269|PubMed:15255109,
FT                                ECO:0000269|PubMed:15475877}.
FT                                /FTId=VAR_054255.
FT   VARIANT     390    390       R -> H (in GLC3A; allele CYP1B1*21;
FT                                dbSNP:rs56010818).
FT                                {ECO:0000269|PubMed:15342693,
FT                                ECO:0000269|PubMed:15475877,
FT                                ECO:0000269|PubMed:9497261}.
FT                                /FTId=VAR_008353.
FT   VARIANT     390    390       R -> S (in GLC3A; dbSNP:rs148542782).
FT                                {ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:14635112}.
FT                                /FTId=VAR_054256.
FT   VARIANT     399    399       I -> S (in GLC3A; dbSNP:rs72549378).
FT                                {ECO:0000269|PubMed:14635112}.
FT                                /FTId=VAR_054257.
FT   VARIANT     409    409       V -> F (in POAG).
FT                                {ECO:0000269|PubMed:16862072}.
FT                                /FTId=VAR_054258.
FT   VARIANT     422    422       V -> G. {ECO:0000269|PubMed:16490498}.
FT                                /FTId=VAR_054259.
FT   VARIANT     423    423       N -> Y (in GLC3A and POAG; juvenile-
FT                                onset; dbSNP:rs104893629).
FT                                {ECO:0000269|PubMed:14635112,
FT                                ECO:0000269|PubMed:15342693}.
FT                                /FTId=VAR_054260.
FT   VARIANT     432    432       L -> V (in allele CYP1B1*3, allele
FT                                CYP1B1*5, allele CYP1B1*6 and allele
FT                                CYP1B1*7; 1.6-fold increase in 17beta-
FT                                estradiol 4-hydroxylation activity but no
FT                                change in 17beta-estradiol 2-
FT                                hydroxylation activity; 2-fold reduction
FT                                in testosterone 6beta-hydroxylation
FT                                activity and 3-fold reduction in
FT                                testosterone affinity; 6-fold and 4-fold
FT                                increase in progesterone 6beta- and
FT                                16alpha-hydroxylation activity,
FT                                respectively and 7-fold reduction in
FT                                progesterone affinity; dbSNP:rs1056836).
FT                                {ECO:0000269|PubMed:10426814,
FT                                ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:10739169,
FT                                ECO:0000269|PubMed:11527932,
FT                                ECO:0000269|PubMed:11774072,
FT                                ECO:0000269|PubMed:11854439,
FT                                ECO:0000269|PubMed:11980847,
FT                                ECO:0000269|PubMed:12036985,
FT                                ECO:0000269|PubMed:12525557,
FT                                ECO:0000269|PubMed:14635112,
FT                                ECO:0000269|PubMed:15342693,
FT                                ECO:0000269|PubMed:15475877,
FT                                ECO:0000269|PubMed:16688110,
FT                                ECO:0000269|PubMed:9497261,
FT                                ECO:0000269|PubMed:9823305,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_001248.
FT   VARIANT     437    437       P -> L (in GLC3A; allele CYP1B1*23;
FT                                dbSNP:rs56175199).
FT                                {ECO:0000269|PubMed:12036985,
FT                                ECO:0000269|PubMed:15475877,
FT                                ECO:0000269|PubMed:9497261}.
FT                                /FTId=VAR_008354.
FT   VARIANT     441    441       D -> H (in dbSNP:rs4986887).
FT                                /FTId=VAR_028737.
FT   VARIANT     443    443       A -> G (in GLC3A and POAG; allele
FT                                CYP1B1*7; unknown pathological
FT                                significance; dbSNP:rs4986888).
FT                                {ECO:0000269|PubMed:11854439,
FT                                ECO:0000269|PubMed:12036985,
FT                                ECO:0000269|PubMed:15342693,
FT                                ECO:0000269|PubMed:16862072}.
FT                                /FTId=VAR_018774.
FT   VARIANT     444    444       R -> Q (in GLC3A; dbSNP:rs72549376).
FT                                {ECO:0000269|PubMed:11527932}.
FT                                /FTId=VAR_054261.
FT   VARIANT     445    445       F -> C (in GLC3A).
FT                                {ECO:0000269|PubMed:14640114}.
FT                                /FTId=VAR_054262.
FT   VARIANT     449    449       D -> E (in dbSNP:rs1056837).
FT                                /FTId=VAR_028738.
FT   VARIANT     453    453       N -> S (in allele CYP1B1*4;
FT                                dbSNP:rs1800440).
FT                                {ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:11854439,
FT                                ECO:0000269|PubMed:12036985,
FT                                ECO:0000269|PubMed:12525557,
FT                                ECO:0000269|PubMed:14635112,
FT                                ECO:0000269|PubMed:15342693,
FT                                ECO:0000269|PubMed:15475877,
FT                                ECO:0000269|PubMed:16688110,
FT                                ECO:0000269|PubMed:9823305,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_008355.
FT   VARIANT     466    466       G -> D (in GLC3A; dbSNP:rs868208502).
FT                                {ECO:0000269|PubMed:15475877}.
FT                                /FTId=VAR_054263.
FT   VARIANT     469    469       R -> W (in GLC3A; allele CYP1B1*25;
FT                                dbSNP:rs28936701).
FT                                {ECO:0000269|PubMed:10655546,
FT                                ECO:0000269|PubMed:16735994,
FT                                ECO:0000269|PubMed:9463332,
FT                                ECO:0000269|PubMed:9497261}.
FT                                /FTId=VAR_001247.
FT   VARIANT     499    499       E -> G (in GLC3A; dbSNP:rs72549372).
FT                                {ECO:0000269|PubMed:11527932}.
FT                                /FTId=VAR_054264.
FT   VARIANT     515    515       S -> L (in POAG; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16688110}.
FT                                /FTId=VAR_054265.
FT   VARIANT     518    518       V -> A. {ECO:0000269|PubMed:16688110}.
FT                                /FTId=VAR_054266.
FT   VARIANT     523    523       R -> T (in POAG; juvenile-onset).
FT                                {ECO:0000269|PubMed:16688110}.
FT                                /FTId=VAR_054267.
FT   VARIANT     530    530       D -> G (in POAG).
FT                                {ECO:0000269|PubMed:16688110}.
FT                                /FTId=VAR_054268.
FT   MUTAGEN     395    395       V->L: Invertes the 4OH E2:2OH E2
FT                                hydroxylation preference from 5.1 to
FT                                0.45. {ECO:0000269|PubMed:23821647}.
FT   HELIX        70     81       {ECO:0000244|PDB:3PM0}.
FT   STRAND       83     89       {ECO:0000244|PDB:3PM0}.
FT   STRAND       92     97       {ECO:0000244|PDB:3PM0}.
FT   HELIX       100    107       {ECO:0000244|PDB:3PM0}.
FT   TURN        108    113       {ECO:0000244|PDB:3PM0}.
FT   HELIX       121    125       {ECO:0000244|PDB:3PM0}.
FT   HELIX       126    129       {ECO:0000244|PDB:3PM0}.
FT   STRAND      132    135       {ECO:0000244|PDB:3PM0}.
FT   HELIX       139    154       {ECO:0000244|PDB:3PM0}.
FT   HELIX       162    183       {ECO:0000244|PDB:3PM0}.
FT   HELIX       184    188       {ECO:0000244|PDB:3PM0}.
FT   HELIX       194    209       {ECO:0000244|PDB:3PM0}.
FT   HELIX       219    224       {ECO:0000244|PDB:3PM0}.
FT   HELIX       228    235       {ECO:0000244|PDB:3PM0}.
FT   TURN        241    243       {ECO:0000244|PDB:3PM0}.
FT   HELIX       245    249       {ECO:0000244|PDB:3PM0}.
FT   HELIX       253    282       {ECO:0000244|PDB:3PM0}.
FT   HELIX       292    304       {ECO:0000244|PDB:3PM0}.
FT   HELIX       317    319       {ECO:0000244|PDB:3PM0}.
FT   HELIX       320    348       {ECO:0000244|PDB:3PM0}.
FT   HELIX       350    363       {ECO:0000244|PDB:3PM0}.
FT   HELIX       372    377       {ECO:0000244|PDB:3PM0}.
FT   HELIX       379    392       {ECO:0000244|PDB:3PM0}.
FT   STRAND      407    409       {ECO:0000244|PDB:3PM0}.
FT   STRAND      412    414       {ECO:0000244|PDB:3PM0}.
FT   STRAND      419    424       {ECO:0000244|PDB:3PM0}.
FT   HELIX       425    428       {ECO:0000244|PDB:3PM0}.
FT   TURN        431    433       {ECO:0000244|PDB:3PM0}.
FT   STRAND      435    439       {ECO:0000244|PDB:3PM0}.
FT   HELIX       442    445       {ECO:0000244|PDB:3PM0}.
FT   HELIX       454    457       {ECO:0000244|PDB:3PM0}.
FT   HELIX       473    490       {ECO:0000244|PDB:3PM0}.
FT   STRAND      491    495       {ECO:0000244|PDB:3PM0}.
FT   STRAND      505    513       {ECO:0000244|PDB:3PM0}.
FT   STRAND      518    524       {ECO:0000244|PDB:3PM0}.
SQ   SEQUENCE   543 AA;  60846 MW;  46B6DA7368F63EA2 CRC64;
     MGTSLSPNDP WPLNPLSIQQ TTLLLLLSVL ATVHVGQRLL RQRRRQLRSA PPGPFAWPLI
     GNAAAVGQAA HLSFARLARR YGDVFQIRLG SCPIVVLNGE RAIHQALVQQ GSAFADRPAF
     ASFRVVSGGR SMAFGHYSEH WKVQRRAAHS MMRNFFTRQP RSRQVLEGHV LSEARELVAL
     LVRGSADGAF LDPRPLTVVA VANVMSAVCF GCRYSHDDPE FRELLSHNEE FGRTVGAGSL
     VDVMPWLQYF PNPVRTVFRE FEQLNRNFSN FILDKFLRHC ESLRPGAAPR DMMDAFILSA
     EKKAAGDSHG GGARLDLENV PATITDIFGA SQDTLSTALQ WLLLLFTRYP DVQTRVQAEL
     DQVVGRDRLP CMGDQPNLPY VLAFLYEAMR FSSFVPVTIP HATTANTSVL GYHIPKDTVV
     FVNQWSVNHD PLKWPNPENF DPARFLDKDG LINKDLTSRV MIFSVGKRRC IGEELSKMQL
     FLFISILAHQ CDFRANPNEP AKMNFSYGLT IKPKSFKVNV TLRESMELLD SAVQNLQAKE
     TCQ
//
